Warning:
JavaScript is turned OFF. None of the links on this page will work until it is reactivated.
If you need help turning JavaScript On, click here.
This Concept Map, created with IHMC CmapTools, has information related to: 16.11, BCR-ABL oncoprotein activates Myc, Tumors that reoccur still exhibit the BCR-ABL oncoprotein, Gleevec stabalizes an inactive form of the Tyrosine Kinase, Gleevec also targets KIT, Philadelphia Chromosome was a fusion os chromosome 9, BCR-ABL oncoprotein activates Jak-STAT, Gleevec works well with Src Antagonists, Src Antagonists inhibit Tyrosine Kinase, Philadelphia Chromosome is found in Chronic Myelogenous Leukemia(CML), Gleevec effects are limited by Cancer Stem Cells, BCR-ABL oncoprotein activates Ras, Gleevec is a theraputic drug that targets BCR-ABL oncoprotein, KIT mutations cause GIST's, Gleevec also targets PDGF-R, BCR-ABL oncoprotein is located on the Philadelphia Chromosome, Philadelphia Chromosome was a fusion os chromosome 22, Gleevec is a theraputic drug that targets Tumors, PDGF-R mutations are responsible for Medulla Blastomas, BCR-ABL oncoprotein acts as an active Tyrosine Kinase, BCR-ABL oncoprotein activates P13K